Fierce Pharma12h
Novo's commercial strategy head hits the exit, prompting a slew of executive team shakeups
Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...
Denmark Stocks Slide Into Bear Market as Tariffs, Novo Weigh
Denmark’s benchmark stock index has fallen 21% from its September high, making it the first major European index to enter a bear market as tariff-related risks and a slump for Novo Nordisk A/S weigh.
Novo Nordisk Announces Changes In Executive Management
After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company.
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
CNBC on MSN7d
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...
Novo Nordisk Stock (NVO) Sees Its Largest Monthly Drop Since 2002
Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...
Pharmabiz2d
Novo Nordisk presents positive results from SOUL cardiovascular outcomes trial of Rybelsus at ACC’s annual scientific session
Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors ...
NBC Chicago7d
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss ...